drugset / Trial / NCT01552343

Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary

NCT01552343

Phase 3 Completed 56 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess psychometric properties (reliability and validity) of the Nocturia Impact (NI) diary. To assess the association between reduction of number of nocturnal voids and the mean changes in NI scores (sensitivity of the NI total score to change in nocturia). To assess which NI diary items account for the main difference in change in total NI score in treatment versus placebo.

Timeline

Start
2012-03
Primary completion
2012-05
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Desmopressin Peptide 25 ug Oral
Subject Desmopressin Peptide 75 ug Oral

Indications